Dr. Adi Mor, CEO and CSO
ChemomAb is managed by Dr. Mor, who co-founded the company in 2011. Dr. Mor has extensive knowledge and experience in the fields of immunology, autoimmune and inflammatory diseases and a wide experience in designing, promoting and patenting a novel class of monoclonal antibodies to treat inflammatory and cancer diseases. Dr. Mor completed her Ph.D. in Immunology from the Tel Aviv University in the Department of Neurobiochemistry and is a lead author of multiple publications in scientific journals in the fields of immunology and inflammatory disorders.
Dr. Arnon Aharon, Head of Clinical development
Dr. Aharon joined ChemomAb in 2016 as head of clinical development. Prior to joining ChemomAb, Dr. Aharon served as Chief Medical Officer at BioLineRx Ltd. (NASDAQ/TASE: BLRX). In BioLineRx he was responsible for the development of the company’s pipeline focused on oncology and immunology. Dr. Aharon is a founder and partner in R&D Integrative Solutions, a firm that provides consulting services to the biotechnology industry and academic centers. Prior to the establishment of R&D Integrative Solutions Dr. Aharon served in several management positions including Clinical Director, Medical Director, VP of Development at several biotechnology companies, such as Pharmos Ltd. (NASDAQ/TASE: PARX); Thrombotech Ltd.; and LycoRed Ltd. Dr. Aharon holds an M.D degree from the University of Tel Aviv, Israel and has experience in internal medicine.
Dr. Sharon Hashmueli, Head of CMC and Regulatory Affairs
Dr. Sharon Hashmueli joined ChemomAb in 2016 as head of CMC and regulatory affairs with over 15 years of experience in drug development, and is responsible for the pre-clinical safety evaluations, regulatory affairs, GMP manufacturing and clinical operations. Prior to joining ChemomAb, Dr. Hashmueli worked at cCAM Biotherapeutics (acquired by Merck in 2015) developing a novel immune checkpoint inhibitor for cancer, and beforehand at Protalix Biotherapeutics, where she played a significant role in the development of Elelyso, an FDA approved treatment for Gauche disease (marketed by Pfizer since 2012). Dr. Hashumueli is experienced in regulatory affairs, including strategic planning, CMC, GMP manufacturing and clinical trial applications for biological products. Her experience also includes pre-clinical and clinical research development in Phase I/II and Phase III global clinical trials. Dr. Hashmueli holds a Ph.D in Biotechnology and Food Engineering from the Technion, Israel Institute of Technology.
Dr. Michal Segal-Salto, Head of Research
Dr. Segal-Salto completed her Ph.D. studies in the molecular mechanism of brain development and neurodegenerative diseases at the Weizmann Institute for Science in Rehovot. Dr. Segal-Salto has vast experience in biochemical and molecular biological methods, including work with in-vitro and in-vivo models.
Dr. Avi Katav, Laboratory Manager
Dr. Katav completed his Ph.D. in Biology at Bar Ilan University where he gained extensive experience in molecular, biochemical and in-vivo work. Dr. Katav is responsible for planning and executing most of the in-vivo and in-vitro work.